MYC targeted therapies offer significant market opportunities, driven by their potential as oncogenic drivers in diverse tumors. The field sees growing R&D on innovative platforms, early-stage ...

The report on Uveitis clinical trials highlights opportunities in understanding trial count, enrollment trends, and successful trial regions. It aids strategic investment decisions by identifying key ...

The report identifies opportunities in optimizing clinical trial strategies and locations, highlighting key market positions in cholera research. It aids in strategy formulation by providing insights ...

The "DNA Cancer Vaccine Clinical Trials, Development Technology Platforms & Market Opportunity Outlook 2026" report has been added to ResearchAndMarkets.com's offering. The global impact of cancer ...

Clinical Trial Investigative Site Network Market was valued at USD 9.2 Bn in 2025 and is projected to reach USD 18.7 Bn by ...

DUBLIN--(BUSINESS WIRE)--The "Global PIM Kinase Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. The market for PIM ...

DUBLIN--(BUSINESS WIRE)--The "Saudi Arabia Clinical Trials Market, Ongoing Clinical Trials by Company, Indication, Phase & Regulations Insight 2025" report has been added to ResearchAndMarkets.com's ...

What Are Clinical Trials for MASH? Clinical trials for MASH are research studies that evaluate potential new treatments for a form of liver disease called metabolic dysfunction-associated ...

The Institute for Healthcare Informatics (IHI) actively supports clinical trials and streamlines the research process through various initiatives: Speed-to-value: We focus on enhancing recruitment and ...

The "OX40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Sana Biotechnology, Inc. announced encouraging preliminary results from a 12-week clinical study involving hypoimmune-modified pancreatic islet cells for type 1 diabetes, showing persistent C-peptide ...